血液学炎症参数与前列腺癌预后价值的研究进展

武 博, 任海 林*
青海大学附属医院泌尿外科

摘要


前列腺癌的发病率正逐年提高，严重威胁着我国人民的健康。准确评估疾病的预后对于前列腺癌患者至
关重要。近年来，多项外周血液学指标在肿瘤患者中的临床应用价值得到重视，以中性粒细胞与淋巴细胞比值
（NLR）、血小板与淋巴细胞比值（PLR）、淋巴细胞与单核细胞比值（LMR）等为主的指标与多种肿瘤预后之间的
显著相关性也得到了证实。本文就当前血液学指标在前列腺癌预后中的研究进展进行综述，并对其未来做出展望。

关键词


血液学指标；前列腺癌；预后

全文:

PDF


参考


[1]Pishgar F, Ebrahimi H, Saeedi Moghaddam S,

Fitzmaurice C, Amini E. Global, Regional and National

Burden of Prostate Cancer, 1990 to 2015: Results

from the Global Burden of Disease Study 2015. J Urol.

2018;199(5):1224-1232. doi:10.1016/j.juro.2017.10.044.

[2]关义满，李沛，房勤茂.磁共振-经直肠超声靶

向穿刺联合病理大切片在前列腺癌诊断中的应用[J].影响

科学与光化学，2022，40（5）：1098-1102.

[3]Boyle WJ, Simonet WS, Lacey DL. Osteoclast

differentiation and activation[J]. Nature,2003,423(6937):337-

342.

[4]李文，王光策，王锁刚.炎症反应在前列腺癌

骨转移中的作用研究进展[J].现代泌尿生殖肿瘤杂志，

2023，15（01）：61-64.

[5]Virchow R. An Address on the Value of Pathological

Experiments. Br Med J. 1881;2(1075):198-203. doi:10.1136/

bmj.2.1075.198.

[6]Kawanishi S, Ohnishi S, Ma N, et al. Crosstalk

between DNA damage and inflammation in the multiple steps

of carcinogen esis. Int J Mol Sci. 2017;18(8).

[7]Suresh V, Dash P, Suklabaidya S, et al. MIF confers

survival advantage to pancreatic CAFs by suppressing

interferon pathway-induced p53-dependent apoptosis.

FASEB J. 2022;36(8):e22449. doi:10.1096/fj.202101953R.

[8]Propper DJ, Balkwill FR. Harnessing cytokines

and chemokines for cancer therapy. Nat Rev Clin Oncol.

2022;19(4):237-253. doi:10.1038/s41571-021-00588-9.

[9]Uribe-Querol E, Rosales C. Neutrophils in

Cancer: Two Sides of the Same Coin. J Immunol Res.

2015;2015:983698. doi:10.1155/2015/983698.

[10]Liu W, Kuang T, Liu L, Deng W. The role

of innate immune cells in the colorectal cancer tumor

microenvironment and advances in anti-tumor therapy

research. Front Immunol. 2024;15:1407449. Published 2024

Jul 19. doi:10.3389/fimmu.2024.1407449.

[11]He Y, Liu X, Wang M, et al. Neutrophil-tolymphocyte ratio as a predictor of cardiovascular mortality

in cancer survivors. Sci Rep. 2024 Sep 9;14(1):20980. doi:

10.1038/s41598-024-72027-5.

[12]Taussky D, Soulieres D, Chagnon M, et al. Systemic

Inflammatory Markers Are Predictive of the Response to

Brachytherapy in the Prostate. Cells. 2020 Sep 23;9(10):2153.doi: 10.3390/cells9102153.

[13]Wang S, Yang X, Yu Z, et al. The Values of

Systemic Immune-Inflammation Index and NeutrophilLymphocyte Ratio in Predicting Biochemical Recurrence

in Patients With Localized Prostate Cancer After Radical

Prostatectomy. Front Oncol. 2022 Jun 2;12:907625. doi:

10.3389/fonc.2022.907625.

[14]Zapała P, Garbas K, Lewandowski Z, et al.

Neutrophil-to-lymphocyte ratio predicts nodal involvement

in unfavourable, clinically nonmetastatic prostate cancer

patients and overall survival in pN1 patients. Sci Rep. 2023

Jan 9;13(1):392. doi: 10.1038/s41598-023-27542-2.

[15]Wallis CJD, Shayegan B, Morgan SC, et al.

Prognostic Association between Common Laboratory Tests

and Overall Survival in Elderly Men with De Novo Metastatic

Castration Sensitive Prostate Cancer: A Population-Based

Study in Canada. Cancers (Basel). 2021 Jun 7;13(11):2844.

doi: 10.3390/cancers13112844.

[16]Pisano C, Tucci M, DI Stefano RF, et al. Prognostic

role of platelet-to-lymphocyte ratio and neutrophil-tolymphocyte ratio in patients with metastatic castration resistant

prostate cancer treated with abiraterone or enzalutamide.

Minerva Urol Nephrol. 2021 Dec;73(6):803-814. doi:

10.23736/S2724-6051.21.04186-2.

[17]Salciccia S, Frisenda M, Bevilacqua G, et al.

Comparative Prospective and Longitudinal Analysis on the

Platelet-to-Lymphocyte, Neutrophil-to-Lymphocyte,

and Albumin-to-Globulin Ratio in Patients with NonMetastatic and Metastatic Prostate Cancer. Curr Oncol. 2022

Dec 3;29(12):9474-9500. doi: 10.3390/curroncol29120745.

[18]董超男，翟文萍，王雪野.血小板介导肿瘤细胞

生长和转移的机制研究进展[J].医学综述，2020，26（04）：

695-699.

[19]Angusti T, DI Stefano RF, Parente A, et al.

Prognostic factors in metastatic castration resistant prostate

cancer patients treated with radium-223: a retrospective

study. Minerva Urol Nephrol. 2022 Dec;74(6):703-713. doi:

10.23736/S2724-6051.22.04701-2.

[20]Jakubzick CV, Randolph GJ, Henson PM.

Monocyte differentiation and antigen-presenting functions.

Nat Rev Immunol. 2017;17(6):349-362. doi:10.1038/

nri.2017.28.

[21]Ugel S, Canè S, De Sanctis F, Bronte V.

Monocytes in the Tumor Microenvironment. Annu

Rev Pathol. 2021;16:93-122. doi:10.1146/annurevpathmechdis-012418-013058.

[22]Huszno J, Kołosza Z, Mrochem-Kwarciak J, et al.

Role of neutrophil-lymphocyte ratio, platelet-lymphocyte

ratio, lymphocyte-monocyte ratio and platelets in prognosis

of patients with prostate cancer. Oncol Lett. 2022 Jul

8;24(3):305. doi: 10.3892/ol.2022.13425.

[23]Lu N, Sheng S, Xiong Y, et al. Prognostic model

for predicting recurrence in hepatocellular carcinoma patients

with high systemic immune-inflammation index based on

machine learning in a multicenter study. Front Immunol.

2024 Sep 9;15:1459740. doi: 10.3389/fimmu.2024.1459740.

[24]Tay F, Buyukkor M, Duran AO. Prognostic

Importance of Combined Use of MELD Scores and SII in

Hepatic Visceral Crisis in Patients with Solid Tumours. J

Coll Physicians Surg Pak. 2023 Aug;33(8):879-883. doi:

10.29271/jcpsp.2023.08.879.

[25]Wang Q, Zhu SR, Huang XP, et al. Prognostic

value of systemic immune-inflammation index in patients

with urinary system cancers: a meta-analysis. Eur Rev Med

Pharmacol Sci. 2021 Feb;25(3):1302-1310. doi: 10.26355/

eurrev_202102_24834.

[26]Meng L, Yang Y, Hu X, et al. Prognostic value of

the pretreatment systemic immune-inflammation index in

patients with prostate cancer: a systematic review and metaanalysis. J Transl Med. 2023 Feb 4;21(1):79. doi: 10.1186/

s12967-023-03924-y.

[27]Rajwa P, Schuettfort VM, D’Andrea D, et

al. Impact of systemic Immune-inflammation Index

on oncologic outcomes in patients treated with radical

prostatectomy for clinically nonmetastatic prostate cancer.

Urol Oncol. 2021 Nov;39(11):785.e19-785.e27. doi:

10.1016/j.urolonc.2021.05.002.

[28]Wu R, Hu M, Zhang P. Predictive value of

systematic immune-inflammation index combined with

Ki-67 index on prognosis of prostate cancer patients after

laparoscopic radical prostatectomy. BMC Urol. 2023 Dec

19;23(1):210. doi: 10.1186/s12894-023-01379-3.

[29]Rajwa P, Schuettfort VM, Quhal F, et al. Role

of systemic immune-inflammation index in patients

treated with salvage radical prostatectomy. World J Urol.

2021;39(10):3771-3779. doi:10.1007/s00345-021-03715-4.[30]Man YN, Chen YF. Systemic immuneinflammation index, serum albumin, and fibrinogen impact

prognosis in castration-resistant prostate cancer patients

treated with first-line docetaxel. Int Urol Nephrol. 2019

Dec;51(12):2189-2199. doi: 10.1007/s11255-019-02265-4.

[31]Kayar R, Tokuc E, Ozsoy E, et al. The predictive

impact of hematological inflammatory markers in detecting

prostate cancer in patients with PI-RADS 3 lesions on

multiparametric magnetic resonance imaging. Prostate. 2024

Sep;84(13):1244-1250. doi: 10.1002/pros.24762.

[32]Hua X, Long ZQ, Huang X, et al. The preoperative

systemic inflammation response index (SIRI) independently

predicts survival in postmenopausal women with breast

cancer. Curr Probl Cancer. 2020;44(4):100560. doi:10.1016/

j.currproblcancer.2020.100560.

[33]Kiely M, Ambs S. Immune Inflammation Pathways

as Therapeutic Targets to Reduce Lethal Prostate Cancer in

African American Men. Cancers (Basel). 2021;13(12):2874.

Published 2021 Jun 9. doi:10.3390/cancers13122874.

[34]Bailey-Whyte M, Minas TZ, Dorsey TH, et al.

Systemic Inflammation Indices and Association with Prostate

Cancer Survival in a Diverse Patient Cohort. Cancers (Basel).

2023;15(6):1869. Published 2023 Mar 20. doi:10.3390/

cancers15061869.

[35]Alessi JV, Ricciuti B, Alden SL, et al. Low peripheral

blood derived neutrophil-to-lymphocyte ratio (dNLR)

is associated with increased tumor T-cell infiltration and

favorable outcomes to first-line pembrolizumab in non-small

cell lung cancer. J Immunother Cancer. 2021;9(11):e003536.

doi:10.1136/jitc-2021-003536.

[36]Kim, C.G.; Kim, M.H.; Kim, J.H.; et al. “Ontreatment derived neutrophil-to-lymphocyte ratio and

survival with palbociclib and endocrine treatment: analysis of

a multicenter retrospective cohort and the PALOMA-2/3

study with immune correlates.” Breast cancer research : BCR

vol. 25,1 4. 12 Jan. 2023, doi:10.1186/s13058-022-01601-4.

[37]Li, C.; Wu, J.; Jiang, L.; et al. “The predictive value

of inflammatory biomarkers for major pathological response

in non-small cell lung cancer patients receiving neoadjuvant

chemoimmunotherapy and its association with the immunerelated tumor microenvironment: a multi-center study.”

Cancer immunology, immunotherapy : CII vol. 72,3 (2023):

783-794. doi:10.1007/s00262-022-03262-w.

[38]Colloca, G.A.; Venturino, A.; Guarneri, D.

“Reduction of derived neutrophil-to-lymphocyte ratio

after four weeks predicts the outcome of patients receiving

second-line chemotherapy for metastatic colorectal cancer.”

Cancer immunology, immunotherapy : CII vol. 70,4 (2021):

1115-1125. doi:10.1007/s00262-020-02761-y.

[39]Dalpiaz, O et al. “Validation of the pretreatment

derived neutrophil-lymphocyte ratio as a prognostic factor

in a European cohort of patients with upper tract urothelial

carcinoma.”British journal of cancer vol. 110,10 (2014):

2531-6. doi:10.1038/bjc.2014.180.

[40]Rebuzzi, Sara Elena et al. “Inflammatory indices

and clinical factors in metastatic renal cell carcinoma patients

treated with nivolumab: the development of a novel

prognostic score (Meet-URO 15 study).” Therapeutic

advances in medical oncology vol. 13 17588359211019642.

18 May. 2021, doi:10.1177/17588359211019642.

[41]Rajwa P, Huebner NA, Hostermann DI, et

al. Evaluation of the Predictive Role of Blood-Based

Biomarkers in the Context of Suspicious Prostate MRI in

Patients Undergoing Prostate Biopsy. J Pers Med. 2021 Nov

19;11(11):1231. doi: 10.3390/jpm11111231.

[42]Yamada Y, Sakamoto S, Rii J, Yamamoto S,

Kamada S, Imamura Y, Nakamura K, Komiya A, Nakatsu H,

Ichikawa T. Prognostic value of an inflammatory index for

patients with metastatic castration-resistant prostate cancer.

Prostate. 2020 May;80(7):559-569. doi: 10.1002/pros.23969.

Epub 2020 Mar 5.

[43]Qiu R, Bu K, An H, et al. A retrospective study:

analysis of the relationship between lactate dehydrogenase and

castration-resistant prostate cancer based on restricted cubic

spline model. PeerJ. 2023 Oct 6;11:e16158. doi: 10.7717/

peerj.16158.

[44]Herranz-Bayo E, Chara-Velarde LE, CassinelloEspinosa J, et al. Lung immune prognostic index (LIPI) as a

prognostic factor in patients with extensive-stage small cell lung

cancer treated with first-line chemoimmunotherapy. Clin Transl

Oncol. 2024 Sep 6. doi: 10.1007/s12094-024-03690-3.

[45]Wang Z, Liu H, Zhu Q, et al. Analysis of the

immune-inflammatory indices for patients with metastatic

hormone-sensitive and castration-resistant prostate cancer.

BMC Cancer. 2024 Jul 9;24(1):817. doi: 10.1186/s12885-

024-12593-z.


Refbacks

  • 当前没有refback。